1.Caregiver Burden of Patients With Huntington’s Disease in South Korea
Chan Young LEE ; Chaewon SHIN ; Yun Su HWANG ; Eungseok OH ; Manho KIM ; Hyun Sook KIM ; Sun Ju CHUNG ; Young Hee SUNG ; Won Tae YOON ; Jin Whan CHO ; Jae-Hyeok LEE ; Han-Joon KIM ; Hee Jin CHANG ; Beomseok JEON ; Kyung Ah WOO ; Seong-Beom KOH ; Kyum-Yil KWON ; Jangsup MOON ; Young Eun KIM ; Jee-Young LEE
Journal of Movement Disorders 2024;17(1):30-37
		                        		
		                        			 Objective:
		                        			This is the first prospective cohort study of Huntington’s disease (HD) in Korea. This study aimed to investigate the caregiver burden in relation to the characteristics of patients and caregivers. 
		                        		
		                        			Methods:
		                        			From August 2020 to February 2022, we enrolled patients with HD from 13 university hospitals in Korea. We used the 12-item Zarit Burden Interview (ZBI-12) to evaluate the caregiver burden. We evaluated the clinical associations of the ZBI-12 scores by linear regression analysis and investigated the differences between the low- and high-burden groups. 
		                        		
		                        			Results:
		                        			Sixty-five patients with HD and 45 caregivers were enrolled in this cohort study. The average age at onset of motor symptoms was 49.3 ± 12.3 years, with an average cytosine-adenine-guanine (CAG)n of 42.9 ± 4.0 (38–65). The median ZBI-12 score among our caregivers was 17.6 ± 14.2. A higher caregiver burden was associated with a more severe Shoulson–Fahn stage (p = 0.038) of the patients. A higher ZBI-12 score was also associated with lower independence scale (B = -0.154, p = 0.006) and functional capacity (B = -1.082, p = 0.002) scores of patients. The caregiving duration was longer in the high- than in the low-burden group. Caregivers’ demographics, blood relation, and marital and social status did not affect the burden significantly. 
		                        		
		                        			Conclusion
		                        			HD patients’ neurological status exerts an enormous impact on the caregiver burden regardless of the demographic or social status of the caregiver. This study emphasizes the need to establish an optimal support system for families dealing with HD in Korea. A future longitudinal analysis could help us understand how disease progression aggravates the caregiver burden throughout the entire disease course. 
		                        		
		                        		
		                        		
		                        	
2.Evaluating the Validity and Reliability of the Korean Version of the Scales for Outcomes in Parkinson’s Disease–Cognition
Jinse PARK ; Eungseok OH ; Seong-Beom KOH ; In-Uk SONG ; Tae-Beom AHN ; Sang Jin KIM ; Sang-Myung CHEON ; Yoon-Joong KIM ; Jin Whan CHO ; Hyeo-Il MA ; Mee Young PARK ; Jong Sam BAIK ; Phil Hyu LEE ; Sun Ju CHUNG ; Jong-Min KIM ; Han-Joon KIM ; Young-Hee SUNG ; Do Young KWON ; Jae-Hyeok LEE ; Jee-Young LEE ; Ji Seon KIM ; Ji Young YUN ; Hee Jin KIM ; Jin Yong HONG ; Mi-Jung KIM ; Jinyoung YOUN ; Hui-Jun YANG ; Won Tae YOON ; Sooyeoun YOU ; Kyum-Yil KWON ; Su-Yun LEE ; Younsoo KIM ; Hee-Tae KIM ; Joong-Seok KIM ; Ji-Young KIM
Journal of Movement Disorders 2024;17(3):328-332
		                        		
		                        			 Objective:
		                        			The Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA-Cog) was developed to assess cognition in patients with Parkinson’s disease (PD). In this study, we aimed to evaluate the validity and reliability of the Korean version of the SCOPACog (K-SCOPA-Cog). 
		                        		
		                        			Methods:
		                        			We enrolled 129 PD patients with movement disorders from 31 clinics in South Korea. The original version of the SCOPA-Cog was translated into Korean using the translation-retranslation method. The test–retest method with an intraclass correlation coefficient (ICC) and Cronbach’s alpha coefficient were used to assess reliability. Spearman’s rank correlation analysis with the Montreal Cognitive Assessment-Korean version (MOCA-K) and the Korean Mini-Mental State Examination (K-MMSE) were used to assess concurrent validity. 
		                        		
		                        			Results:
		                        			The Cronbach’s alpha coefficient was 0.797, and the ICC was 0.887. Spearman’s rank correlation analysis revealed a significant correlation with the K-MMSE and MOCA-K scores (r = 0.546 and r = 0.683, respectively). 
		                        		
		                        			Conclusion
		                        			Our results demonstrate that the K-SCOPA-Cog has good reliability and validity. 
		                        		
		                        		
		                        		
		                        	
3.Reaching New Heights: A Comprehensive Study of Hand Transplantations in Korea after Institutionalization of Hand Transplantation Law
Yo Han KIM ; Yun Rak CHOI ; Dong Jin JOO ; Woo Yeol BAEK ; Young Chul SUH ; Won Taek OH ; Jae Yong CHO ; Sang Chul LEE ; Sang Kyum KIM ; Hyang Joo RYU ; Kyung Ock JEON ; Won Jai LEE ; Jong Won HONG
Yonsei Medical Journal 2024;65(2):108-119
		                        		
		                        			 Purpose:
		                        			With the revision of the Organ and Transplantation Act in 2018, the hand has become legal as an area of transplantable organs in Korea. In January 2021, the first hand allotransplantation since legalization was successfully performed, and we have performed a total of three successful hand transplantation since then. By comparing and incorporating our experiences, this study aimed to provide a comprehensive reconstructive solution for hand amputation in Korea. 
		                        		
		                        			Materials and Methods:
		                        			Recipients were selected through a structured preoperative evaluation, and hand transplantations were performed at the distal forearm level. Postoperatively, patients were treated with three-drug immunosuppressive regimen, and functional outcomes were monitored. 
		                        		
		                        			Results:
		                        			The hand transplantations were performed without intraoperative complications. All patients had partial skin necrosis and underwent additional surgical procedures in 2 months after transplantation. After additional operations, no further severe complications were observed. Also, patients developed acute rejection within 3 months of surgery, but all resolved within 2 weeks after steroid pulse therapy. Motor and sensory function improved dramatically, and patients were very satisfied with the appearance and function of their transplanted hands. 
		                        		
		                        			Conclusion
		                        			Hand transplantation is a viable reconstructive option, and patients have shown positive functional and psychological outcomes. Although this study has limitations, such as the small number of patients and short follow-up period, we should focus on continued recovery of hand function, and be careful not to develop side effects from immunosuppressive drugs. Through the present study, we will continue to strive for a bright future regarding hand transplantation in Korea. 
		                        		
		                        		
		                        		
		                        	
4.Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
Jung Yong HONG ; Hee Jin CHO ; Kum-Hee YUN ; Young Han LEE ; Seung Hyun KIM ; Wooyeol BAEK ; Sang Kyum KIM ; Yurimi LEE ; Yoon-La CHOI ; Minsuk KWON ; Hyo Song KIM ; Jeeyun LEE
Cancer Research and Treatment 2023;55(2):671-683
		                        		
		                        			 Purpose:
		                        			Even though pazopanib, a multitargeted tyrosine kinase inhibitor, has been approved for refractory soft tissue sarcoma (STS), little is known about the molecular determinants of the response to pazopanib. We performed integrative molecular characterization to identify potential predictors of pazopanib efficacy. 
		                        		
		                        			Materials and Methods:
		                        			We obtained fresh pre-treatment tumor tissue from 35 patients with advanced STS receiving pazopanib-based treatment. Among those, 18 (51.4%) received pazopanib monotherapy, and the remaining 17 (48.6%) received pazopanib in combination with durvalumab, programmed death-ligand 1 blockade. Whole-exome and transcriptome sequencing were performed for each tumor and patient germline DNA. 
		                        		
		                        			Results:
		                        			Of the 35 patients receiving pazopanib-based treatment, nine achieved a partial response (PR), resulting in an objective response rate (ORR) of 27.3%, and the median progression-free survival (PFS) was 6.0 months. Patients with CDK4 amplification (copy ratio tumor to normal > 2) exhibited shorter PFS (3.7 vs. 7.9 months, p=2.09×10–4) and a poorer response (ORR; 0% vs. 33.3%) compared to those without a gene amplification (copy ratio ≤ 2). Moreover, non-responders demonstrated transcriptional activation of CDK4 via DNA amplification, resulting in cell cycle activation. In the durvalumab combination cohort, seven of the 17 patients (41.2%) achieved a PR, and gene expression analysis revealed that durvalumab responders exhibited high immune/stromal cell infiltration, mainly comprising natural killer cells, compared to non-responders as well as increased expression of CD19, a B-cell marker. 
		                        		
		                        			Conclusion
		                        			Despite the limitation of heterogeneity in the study population and treatment, we identified possible molecular predictors of pazopanib efficacy that can be employed in future clinical trials aimed at evaluating therapeutic strategies. 
		                        		
		                        		
		                        		
		                        	
5.Validation Study of the Official Korean Version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
Jinse PARK ; Seong-Beom KOH ; Kyum-Yil KWON ; Sang Jin KIM ; Jae Woo KIM ; Joong-Seok KIM ; Kun-Woo PARK ; Jong Sam PAIK ; Young H. SOHN ; Jin-Young AHN ; Eungseok OH ; Jinyoung YOUN ; Ji-Young LEE ; Phil Hyu LEE ; Wooyoung JANG ; Han-Joon KIM ; Beom Seok JEON ; Sun Ju CHUNG ; Jin Whan CHO ; Sang-Myung CHEON ; Suk Yun KANG ; Mee Young PARK ; Seongho PARK ; Young Eun HUH ; Seok Jae KANG ; Hee-Tae KIM
Journal of Clinical Neurology 2021;17(3):501-501
		                        		
		                        		
		                        		
		                        	
6.Validation Study of the Official Korean Version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
Jinse PARK ; Seong-Beom KOH ; Kyum-Yil KWON ; Sang Jin KIM ; Jae Woo KIM ; Joong-Seok KIM ; Kun-Woo PARK ; Jong Sam PAIK ; Young H. SOHN ; Jin-Young AHN ; Eungseok OH ; Jinyoung YOUN ; Ji-Young LEE ; Phil Hyu LEE ; Wooyoung JANG ; Han-Joon KIM ; Beom Seok JEON ; Sun Ju CHUNG ; Jin Whan CHO ; Sang-Myung CHEON ; Suk Yun KANG ; Mee Young PARK ; Seongho PARK ; Young Eun HUH ; Seok Jae KANG ; Hee-Tae KIM
Journal of Clinical Neurology 2021;17(3):501-501
		                        		
		                        		
		                        		
		                        	
7.Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale
Ji-Hyun CHOI ; Jee-Young LEE ; Jin Whan CHO ; Seong-Beom KO ; Tae-Beom AHN ; Sang Jin KIM ; Sang-Myung CHEON ; Joong-Seok KIM ; Yoon-Joong KIM ; Hyeo-Il MA ; Jong Sam BAIK ; Phil Hyu LEE ; Sun Ju CHUNG ; Jong-Min KIM ; In-Uk SONG ; Han-Joon KIM ; Young-Hee SUNG ; Do Young KWON ; Jae-Hyeok LEE ; Ji-Young KIM ; Ji Sun KIM ; Ji Young YUN ; Hee Jin KIM ; Jin Yong HONG ; Mi-Jung Kim KIM ; Jinyoung YOUN ; Ji Seon Kim KIM ; Eung Seok OH ; Hui-Jun YANG ; Won Tae YOON ; Sooyeoun YOU ; Kyum-Yil KWON ; Hyung-Eun PARK ; Su-Yun LEE ; Younsoo KIM ; Hee-Tae KIM ; Mee Young PARK
Journal of Clinical Neurology 2020;16(2):245-253
		                        		
		                        			 Background:
		                        			and PurposeImpulse-control disorder is an important nonmotor symptom of Parkinson's disease (PD) that can lead to financial and social problems, and be related to a poor quality of life. A nationwide multicenter prospective study was performed with the aim of validating the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (K-QUIP-RS). 
		                        		
		                        			Methods:
		                        			The K-QUIP-RS was constructed using forward and backward translation, and pretesting of the prefinal version. PD patients on stable medical condition were recruited from 27 movement-disorder clinics. Participants were assessed using the K-QUIP-RS and evaluated for parkinsonian motor and nonmotor statuses and for PD-related quality of life using a predefined evaluation battery. The test–retest reliability of the K-QUIP-RS was assessed over an interval of 10–14 days, and correlations between the KQUIP-RS and other clinical scales were analyzed. 
		                        		
		                        			Results:
		                        			This study enrolled 136 patients. The internal consistency of the K-QUIP-RS was indicated by a Cronbach's α coefficient of 0.846, as was the test–retest reliability by a Guttman split-half coefficient of 0.808. The total K-QUIP-RS score was positively correlated with the scores for depression and motivation items on the Unified PD Rating Scale (UPDRS), Montgomery-Asberg Depression Scale, and Rapid-Eye-Movement Sleep-Behavior-Disorders Questionnaire. The total K-QUIP-RS score was also correlated with the scores on part II of the UPDRS and the PD Quality of Life-39 questionnaire, and the dopaminergic medication dose. 
		                        		
		                        			Conclusions
		                        			The K-QUIP-RS appears to be a reliable assessment tool for impulse-control and related behavioral disturbances in the Korean PD population. 
		                        		
		                        		
		                        		
		                        	
8.Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean Version of Parkinson's Disease Sleep Scale-2
Hui Jun YANG ; Han Joon KIM ; Seong Beom KOH ; Joong Seok KIM ; Tae Beom AHN ; Sang Myung CHEON ; Jin Whan CHO ; Yoon Joong KIM ; Hyeo Il MA ; Mee Young PARK ; Jong Sam BAIK ; Phil Hyu LEE ; Sun Ju CHUNG ; Jong Min KIM ; In Uk SONG ; Ji Young KIM ; Young Hee SUNG ; Do Young KWON ; Jae Hyeok LEE ; Jee Young LEE ; Ji Seon KIM ; Ji Young YUN ; Hee Jin KIM ; Jin Yong HONG ; Mi Jung KIM ; Jinyoung YOUN ; Ji Sun KIM ; Eung Seok OH ; Won Tae YOON ; Sooyeoun YOU ; Kyum Yil KWON ; Hyung Eun PARK ; Su Yun LEE ; Younsoo KIM ; Hee Tae KIM ; Sang Jin KIM
Journal of Clinical Neurology 2020;16(1):66-74
		                        		
		                        			 BACKGROUND:
		                        			AND PURPOSE: This study aimed to determine the clinimetric properties of the Korean version of Parkinson's Disease Sleep Scale-2 (K-PDSS-2) and whether distinct subtypes of sleep disturbance can be empirically identified in patients with Parkinson's disease (PD) using the cross-culturally validated K-PDSS-2.
		                        		
		                        			METHODS:
		                        			The internal consistency, test–retest reliability, scale precision, and convergent validity of K-PDSS-2 were assessed in a nationwide, multicenter study of 122 patients with PD. Latent class analysis (LCA) was used to derive subgroups of patients who experienced similar patterns of sleep-related problems and nocturnal disabilities.
		                        		
		                        			RESULTS:
		                        			The total K-PDSS-2 score was 11.67±9.87 (mean±standard deviation) at baseline and 12.61±11.17 at the retest. Cronbach's α coefficients of the total K-PDSS-2 scores at baseline and follow-up were 0.851 and 0.880, respectively. The intraclass correlation coefficients over the 2-week study period ranged from 0.672 to 0.848. The total K-PDSS-2 score was strongly correlated with health-related quality of life measures and other corresponding nonmotor scales. LCA revealed three distinct subtypes of sleep disturbance in the study patients: “less-troubled sleepers,â€â€œPD-related nocturnal difficulties,†and “disturbed sleepers.â€
		                        		
		                        			CONCLUSIONS
		                        			K-PDSS-2 showed good clinimetric attributes in accordance with previous studies that employed the original version of the PDSS-2, therefore confirming the cross-cultural usefulness of the scale. This study has further documented the first application of an LCA approach for identifying subtypes of sleep disturbance in patients with PD. 
		                        		
		                        		
		                        		
		                        	
9.Validation Study of the Official Korean Version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
Jinse PARK ; Seong-Beom KOH ; Kyum-Yil KWON ; Sang Jin KIM ; Jae Woo KIM ; Joong-Seok KIM ; Kun-Woo PARK ; Jong Sam PAIK ; Young H. SOHN ; Jin-Young AHN ; Eungseok OH ; Jinyoung YOUN ; Ji-Young LEE ; Phil Hyu LEE ; Wooyoung JANG ; Han-Joon KIM ; Beom Seok JEON ; Sun Ju CHUNG ; Jin Whan CHO ; Sang-Myung CHEON ; Suk Yun KANG ; Mee Young PARK ; Seongho PARK ; Young Eun HUH ; Seok Jae KANG ; Hee-Tae KIM
Journal of Clinical Neurology 2020;16(4):633-645
		                        		
		                        			 Background:
		                        			and Purpose: The Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is widely used for estimating the symptoms of Parkinson’s disease. Translation and validation of the MDS-UPDRS is necessary for non-English speaking countries and regions. The aim of this study was to validate the Korean version of the MDS-UPDRS. 
		                        		
		                        			Methods:
		                        			Altogether, 362 patients in 19 centers were recruited for this study. We translated the MDS-UPDRS to Korean using the translation-back translation method and cognitive pretesting. We performed both confirmatory and exploratory factor analyses to validate the scale.We calculated the comparative fit index (CFI) for confirmatory factor analysis, and used unweighted least squares for exploratory factor analysis. 
		                        		
		                        			Results:
		                        			The CFI was higher than 0.90 for all parts of the scale. Exploratory factor analysis also showed that the Korean MDS-UPDRS has the same number of factors in each part as the English version. 
		                        		
		                        			Conclusions
		                        			The Korean MDS-UPDRS has the same overall structure as the English MDSUPDRS. Our translated scale can be designated as the official Korean MDS-UPDRS. 
		                        		
		                        		
		                        		
		                        	
10.Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Se Hoon LEE ; Boram LEE ; Joon Ho SHIM ; Kwang Woo LEE ; Jae Won YUN ; Sook Young KIM ; Tae You KIM ; Yeul Hong KIM ; Young Hyeh KO ; Hyun Cheol CHUNG ; Chang Sik YU ; Jeeyun LEE ; Sun Young RHA ; Tae Won KIM ; Kyung Hae JUNG ; Seock Ah IM ; Hyeong Gon MOON ; Sukki CHO ; Jin Hyoung KANG ; Jihun KIM ; Sang Kyum KIM ; Han Suk RYU ; Sang Yun HA ; Jong Il KIM ; Yeun Jun CHUNG ; Cheolmin KIM ; Hyung Lae KIM ; Woong Yang PARK ; Dong Young NOH ; Keunchil PARK
Cancer Research and Treatment 2019;51(1):211-222
		                        		
		                        			
		                        			PURPOSE: With the emergence of next-generation sequencing (NGS) technology, profiling a wide range of genomic alterations has become a possibility resulting in improved implementation of targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically actionable genetic alterations has not yet been determined because of a lack of studies examining high-throughput cancer genomic data. MATERIALS AND METHODS: To address this issue, 1,071 tumor samples were collected from five major cancer institutes in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted genomic DNA was assessed. In order to estimate the effect of sample condition on the quality of sequencing results, tissue preparation method, specimen type (resected or biopsied) and tissue storage time were compared. RESULTS: We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions, 3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors had one or more clinically relevant genetic mutation. The distribution of actionable variants was variable among different genes. Fresh frozen tissues, surgically resected specimens, and recently obtained specimens generated superior sequencing results over FFPE tissues, biopsied specimens, and tissues with long storage duration. CONCLUSION: In order to overcome, challenges involved in bringing NGS testing into routine clinical use, a centralized laboratory model was designed that could improve the NGS workflows, provide appropriate turnaround times and control costs with goal of enabling precision medicine.
		                        		
		                        		
		                        		
		                        			Academies and Institutes
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			DNA
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Methods
		                        			;
		                        		
		                        			Paraffin
		                        			;
		                        		
		                        			Point Mutation
		                        			;
		                        		
		                        			Precision Medicine
		                        			;
		                        		
		                        			Prevalence
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail